TrialCritical care (London, England)2022

Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial.

Jean Chastre et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.